Syndax Presents Constructive Revuforj ® (revumenib) Information in Acute Leukemias from A number of Trials, Together with the SAVE Mixture and AUGMENT-101 Trials, at 66th ASH Annual Assembly
“ 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of…
BLINCYTO ® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND…
